SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors


  • Org Study ID: FT516-102
  • Secondary ID:
  • NCT ID: NCT04551885
  • NCT Alias:
  • Sponsor: Fate Therapeutics - Industry
  • Source: Fate Therapeutics

Brief Summary

This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Overal Status Start Date Phase Study Type
Recruiting September 7, 2020 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Incidence of dose-limiting toxicities within each dose level cohort

Primary Outcome 1 - Time Frame: At the end of Cycle 1 (each cycle is 28 days)

Primary Outcome 2 - Measure: Nature of dose-limiting toxicities within each dose level cohort

Primary Outcome 2 - Time Frame: At the end of Cycle 1 (each cycle is 28 days)

Condition:

  • Solid Tumor, Adult

Eligibility

Criteria:
Inclusion Criteria:

- Locally advanced or metastatic solid tumor malignancies that have relapsed or
progressed after at least one line of therapy and where the following anti-PD-L1 are
approved: avelumab, atezolizumab or durvalumabr/>
- Capable of giving signed informed consent

- Aged ≥ 18 years old

- Willingness to comply with study procedures and duration

- Measurable disease per iRECIST

- Contraceptive use for women and men as defined in the protocol

Exclusion Criteria:

- Pregnant or breast-feeding women

- ECOG performance status ≥ 2

- Evidence of insufficient organ function

- Clinically significant cardiovascular disease

- Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is
shorter or any investigational therapy within 28 days prior to Day 1

- Known active central nervous system (CNS) involvement by malignancy

- Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or
neurodegenerative disease or receipt of medications for these conditions

- Currently receiving or likely to require immunosuppressive therapy

- Known active infections with Hepatitis B, Hepatitis C or HIV

- Live vaccine within 6 weeks prior to start of lympho-conditioning

- Known allergy to albumin (human) or DMSO
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Jeff Chou, MD

Role: Study Director

Affiliation: Fate Therapeutics

Overall Contact

Name: DeShaun Noakes

Phone: 858-875-1800

Email: clinical@fatetherapeutics.com

Locations

Facility Status Contact
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota 55455
United States
Recruiting
Hackensack University Medical Center/John Theurer Cancer Center
Hackensack, New Jersey 07601
United States
Recruiting
MD Anderson Cancer Center
Houston, Texas 77030
United States
Not yet recruiting